-
Benzinga's Top Pre-Market Losers
Tuesday, August 23, 2011 - 8:13am | 92Neurocrine Biosciences Inc (NASDAQ: NBIX) fell 3.34% to $5.50 in the pre-market trading. NBIX's trailing-twelve-month ROA is 3.57%. ProShares UltraPro Short QQQ (NASDAQ: SQQQ) dipped 3.20% to $31.50 in the pre-market session. Randgold Resources Limited (NASDAQ: GOLD) lost 1.00% to $112.60 in the...
-
Cell Therapeutics Submits Day 120 Response for Pixantrone Marketing Authorization Application to European Medicines Agency
Tuesday, August 23, 2011 - 6:49am | 136Cell Therapeutics, Inc. (NASDAQ: CTIC) today announced that it has submitted its response to the Day 120 List of Outstanding Issues to the European Medicines Agency's Committee for Medicinal Products for Human Use in regards to CTI's Marketing Authorization Application for pixantrone to treat...
-
Brean Murray Initiates Human Genome Sciences At Buy, $22 PT
Tuesday, August 23, 2011 - 6:26am | 26Brean Murray has initiated coverage on Human Genome Sciences (NASDAQ: HGSI) with a Buy rating and $22 price target.
-
Anadys Pharmaceuticals Appoints Brian S. Posner to Its Board of Directors
Monday, August 22, 2011 - 4:06pm | 80Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the appointment of Brian S. Posner to its Board of Directors. Mr. Posner is currently a private investor and the President and Founder of Point Rider Group LLC. He previously served as the Chief Executive Officer and co-Chief Investment...
-
Breast Cancer Study With Hemispherx Biopharma's Ampligen Commences
Monday, August 22, 2011 - 10:37am | 452Hemispherx Biopharma (NYSE: HEB) announced that investigators from the Tumor Vaccine Group at the University of Washington in Seattle, WA, have enrolled their first patient in their 88 patient "Phase I-II Study of HER2 Vaccination With PolyI - PolyC12U (Ampligen) as an Adjuvant in Optimally Treated...
-
Notable Put Options Activity in BioSante Pharmaceuticals
Monday, August 22, 2011 - 10:33am | 86Shares of BioSante Pharmaceuticals (NASDAQ: BPAX) are higher on the session by 7.43%, currently trading at $2.385. The stock has been moving largely lower over the past two months and is currently trading below the 50-day moving average. Options traders are focusing on puts today. A short while...
-
NASDAQ Stocks Hitting 52-Week Lows
Monday, August 22, 2011 - 10:33am | 133VIST Financial Corp (NASDAQ: VIST) shares fell 2.43% to create a new 52-week low of $6.02. VIST shares have dropped 18.71% over the past 52 weeks, while the S&P 500 index has gained 4.84% in the same period. Synutra International Inc (NASDAQ: SYUT) shares dropped 0.86% to create a new 52-week...
-
Jefferies Comments on Seattle Genetics After Approval of Adcetris
Monday, August 22, 2011 - 9:14am | 98Jefferies has published a research report on Seattle Genetics (NASDAQ: SGEN). In the report, Jefferies wrote, "In spite of a unanimous FDA panel recommendation, there has been pressure on SGEN shares for two reasons. First, there was significant concern about a potential delay in Adcetris approval...
-
Amgen Announces PDUFA Date for XGEVA Supplemental Biologics License Application
Monday, August 22, 2011 - 9:02am | 96Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration will target a Prescription Drug User Fee Act action date of April 26, 2012 for the supplemental Biologics License Application to expand the indication for XGEVA® (denosumab) to treat men with castrate-resistant...
-
Prana Receives Michael J. Fox Foundation Grant to Develop PBT434 for Parkinson's Disease
Monday, August 22, 2011 - 8:59am | 95Prana Biotechnology Limited (NASDAQ: PRAN) announced today that the company has received a grant* from The Michael J. Fox Foundation to support the initiation of pre-clinical studies which precede human trials of a novel treatment for Parkinson's disease known as PBT434. Prana, a leading Australian...
-
Cephalon Gives Notice of Anticipated Fundamental Change to Holders of Its 2.50% Convertible Senior Subordinated Notes due 2014 and 2.00% Convertible Senior Subordinated Notes due 2015
Monday, August 22, 2011 - 8:36am | 208Cephalon, Inc. (Nasdaq: CEPH) today provided notice to holders of its 2.50 percent Convertible Senior Subordinated Notes due 2014 and 2.00 percent Convertible Senior Subordinated Notes due 2015 in respect of the Merger of the Company with a wholly-owned subsidiary of Teva Pharmaceutical Industries...
-
Dendreon Announces Election of John H. Johnson to Board of Directors
Monday, August 22, 2011 - 8:32am | 103Dendreon Corporation (Nasdaq: DNDN) today announced that John H. Johnson has been elected to the Company's Board of Directors, effective August 18, 2011. Mr. Johnson is currently the chief executive officer of Savient Pharmaceuticals, Inc. (Nasdaq: SVNT), where he has also served as a member of its...
-
Piper Jaffray Overweight On Seattle Genetics
Monday, August 22, 2011 - 8:00am | 139Piper Jaffray is out with a research report on Seattle Genetics Inc. (NASDAQ: SGEN) and it has an Overweight rating and a $20 price target on shares. In a note to clients, Piper Jaffray writes, "On Friday August 19th, the FDA granted accelerated approval for ADCETRIS (Brentuximab vedotin) in...
-
Health Canada Approves INCIVEK(TM) (telaprevir) for People With Hepatitis C
Monday, August 22, 2011 - 7:31am | 135Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has approved INCIVEK(TM) (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions),...
-
Oppenheimer Comments on Product Development at United Therapeutics
Monday, August 22, 2011 - 6:45am | 104Oppenheimer has published a research report on United Therapeutics (NASDAQ: UTHR). In the report, Oppenheimer wrote, "UTHR will report key ph.III FREEDOM-C2 results for oral treprostinil in combination with PDE5/ERAs for PAH by the end of August. Based on FREEDOM-M/C results, we believe that oral...